Enal Razvi, PhD is biotechnology analyst and Managing Director US at Select Biosciences
He spoke to Pharma IQ about his recent report on Epigenetic research classes and Assay Trends with Genetic Engineering & Biotechnology News (GEN)
Download PDF Attachment
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
September 9 - 10, 2026
Berlin, Germany
Register Now |
View Agenda |
Learn More